Gabapentin 100/300/400/600/800 mg caps/tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Neuropathic Pain

• Amitriptyline
• Carbamazepine
• Duloxetine
• Pregabalin

About Gabapentin 100/300/400/600/800 mg caps/tabs

Gabapentin, available in strengths ranging from 100mg to 800mg capsules and tablets, is a widely prescribed medication. If you're managing chronic conditions, understanding your treatment is key. At TheDrugClub, we believe in making essential medications like gabapentin affordable, offering significant savings and convenience to our valued members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Gabapentin 100/300/400/600/800 mg caps/tabs is approved for (FDA label)

NEURONTIN ® is indicated for: • Management of postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy NEURONTIN is indicated for: • Postherpetic neuralgia in adults ( 1 ) • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: May 12, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Gabapentin 100/300/400/600/800 mg caps/tabs (FDA label)

Capsules • 100 mg: white hard gelatin capsules printed with “VLE” on the body and “Neurontin/100 mg” on the cap • 300 mg: yellow hard gelatin capsules printed with “VLE” on the body and “Neurontin/300 mg” on the cap • 400 mg: orange hard gelatin capsules printed with “VLE” on the body and “Neurontin/400 mg” on the cap Tablets • 600 mg: white elliptical film-coated scored tablets debossed with “NT” and “16” on one side • 800 mg: white elliptical film-coated scored tablets debossed with “NT” and “26” on one side Oral solution • 250 mg per 5 mL (50 mg per mL), clear colorless to slightly yellow solution • Capsules: 100 mg, 300 mg, and 400 mg ( 3 ) • Tablets: 600 mg, and 800 mg ( 3 ) • Oral Solution: 250 mg/5mL ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 97935fd9-1d4a-43b6-a5d9-de994591187b. SPL document ID: 2d43f32d-2d96-4011-84ac-507c3307dc27. Label effective date: May 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Gabapentin 100/300/400/600/800 mg caps/tabs (FDA label)

The following serious adverse reactions are discussed in greater detail in other sections: • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions (5.1) ] • Anaphylaxis and Angioedema [see Warnings and Precautions (5.2) ] • Somnolence/Sedation and Dizziness [see Warnings and Precautions (5.4) ] • Suicidal Behavior and Ideation [see Warnings and Precautions (5.5) ] • Increased Risk of Seizures and Other Adverse Reactions with Abrupt or Rapid Discontinuation [see Warnings and Precautions (5.6) ] • Status Epilepticus [see Warnings and Precautions (5.7) ] • Respiratory Depression [see Warnings and Precautions (5.8) ] • Neuropsychiatric Adverse Reactions (Pediatric Patients 3 to 12 Years of Age) [see Warnings and Precautions (5.9) ] Most common adverse reactions (incidence ≥8% and at least twice that for placebo) were: • Postherpetic neuralgia: Dizziness, somnolence, and peripheral edema ( 6.1 ) • Epilepsy in patients >12 years of age: Somnolence, dizziness, ataxia, fatigue, and nystagmus ( 6.1 ) • Epilepsy in patients 3 to 12 years of age: Viral infection, fever, nausea and/or vomiting, somnolence, and hostility ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 97935fd9-1d4a-43b6-a5d9-de994591187b. SPL document ID: 2d43f32d-2d96-4011-84ac-507c3307dc27. Label effective date: May 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Gabapentin 100/300/400/600/800 mg caps/tabs (FDA label)

NEURONTIN is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. Known hypersensitivity to gabapentin or its ingredients ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 97935fd9-1d4a-43b6-a5d9-de994591187b. SPL document ID: 2d43f32d-2d96-4011-84ac-507c3307dc27. Label effective date: May 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Gabapentin 100/300/400/600/800 mg caps/tabs (FDA label)

• Drug Reaction with Eosinophilia and Systemic Symptoms (Multiorgan hypersensitivity): Discontinue if alternative etiology is not established ( 5.1 ) • Anaphylaxis and Angioedema: Discontinue and evaluate patient immediately ( 5.2 ) • Driving Impairment; Somnolence/Sedation and Dizziness: Warn patients not to drive until they have gained sufficient experience to assess whether their ability to drive or operate heavy machinery will be impaired ( 5.3 , 5.4 ) • Suicidal Behavior and Ideation: Monitor for suicidal thoughts/behavior ( 5.5 ) • Abrupt or rapid discontinuation may increase the risk for seizures. Withdrawal symptoms, or suicidal behavior and ideation have been observed after discontinuation ( 5.6 ) • Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment.

Source: FDA prescribing information (DailyMed). Set ID: 97935fd9-1d4a-43b6-a5d9-de994591187b. SPL document ID: 2d43f32d-2d96-4011-84ac-507c3307dc27. Label effective date: May 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Gabapentin 100/300/400/600/800 mg caps/tabs (FDA label)

Concentrations increased by morphine; may need dose adjustment ( 5.4 , 7.1 ) 7.1 Opioids Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e.g., morphine, hydrocodone, oxycodone, buprenorphine) [see Warnings and Precautions (5.8) ] . Hydrocodone Coadministration of NEURONTIN with hydrocodone decreases hydrocodone exposure [see Clinical Pharmacology (12.3) ] . The potential for alteration in hydrocodone exposure and effect should be considered when NEURONTIN is started or discontinued in a patient taking hydrocodone.

Source: FDA prescribing information (DailyMed). Set ID: 97935fd9-1d4a-43b6-a5d9-de994591187b. SPL document ID: 2d43f32d-2d96-4011-84ac-507c3307dc27. Label effective date: May 12, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.